Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? Consider the alternatives, after all. And what better way to make the time fly than to keep busy. So grab that cup of stimulation — our flavor today boasts the aroma of blueberries — and get started. Once again, we have a menu of tidbits to get you going. Meanwhile, do keep us in mind if you hear anything interesting. Have a smashing day. …
In seeking to block Amgen from acquiring Horizon Therapeutics over concerns about monopolies, the U.S. Federal Trade Commission cast a spotlight on a practice known as bundling, STAT explains. Simply put, this occurs when a drug company combines two or more medicines in a package deal for health plans and pharmacy benefit managers, which determine lists of medicines that are covered by insurance. The maneuver has previously sparked concerns that a drug company will unfairly offer higher rebates for bundles in order to win favorable formulary placements. By doing so, the regulatory agency is concerned this can drive up consumer costs.
U.S. Food and Drug Administration staffers reported that an experimental RSV vaccine developed by Pfizer to protect infants — by vaccinating pregnant women — was effective in preventing severe lower respiratory tract disease, STAT writes. The agency analysis, which was released ahead of an advisory panel meeting on Thursday, also revealed a slightly higher proportion of preterm births of babies whose moms got the experimental vaccine compared with those given a placebo. A Pfizer trial found the shot was 82% effective at preventing severe disease from RSV in newborns during the first 90 days of life. The FDA is slated to make a decision on whether to clear the shot in August.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect